BRCA1 mutations and prostate cancer in Poland

European Journal of Cancer Prevention

Volumn 17, Issue 1, 2008, Pages 62-66

  Cybulski, Cezary ^a,b   Górski, Bohdan ^a   Gronwald, Jacek ^a   Huzarski, Tomasz ^a   Byrski, Tomasz ^a   Dȩbniak, Tadeusz ^a   Jakubowska, Anna ^a   Wokołorczyk, Dominika ^a   Gliniewicz, Bartłomiej ^b   Sikorski, Andrzej ^b   Stawicka, Małgorzata ^c   Godlewski, Dariusz ^c   Kwias, Zbigniew ^c   Antczak, Andrzej ^c   Krajka, Kazimierz ^d   Lauer, Wojciech ^d   Sosnowski, Marek ^e   Sikorska Radek, Paulina ^f   Bar, Krzysztof ^g   Klijer, Robert ^g   Romuald, Zdrojowy ^g   Małkiewicz, Bartosz ^g   Borkowski, Andrzej ^h   Borkowski, Tomasz ^h   Szwiec, Marek ⁱ   Posmyk, Michal ⁱ   Narod, Steven A ^j   Lubiński, Jan ^a   more..

^a International Hereditary Cancer Center   (Poland)

^b POMERANIAN MEDICAL UNIVERSITY   (Poland)

^c POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^d MEDICAL UNIVERSITY OF GDANSK   (Poland)

^e MEDICAL UNIVERSITY OF LODZ   (Poland)

^f Clinic of Urology Regional Hospital   (Poland)

^g MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^h MEDICAL UNIVERSITY OF WARSAW   (Poland)

ⁱ Regional Oncology Hospital   (Poland)

^j Centre for Research on Women's Health   (Canada)

more..

Author keywords

BRCA1; Hereditary; Prostate cancer

Indexed keywords

BRCA1 PROTEIN;

ADULT; AGED; ARTICLE; CANCER RISK; CARCINOGENESIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; GENE DELETION; GENE FREQUENCY; GENE INSERTION; GENETIC RISK; GENOTYPE; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; ONCOGENE; POLAND; POPULATION GENETICS; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT;

ADULT; AGED; AGED, 80 AND OVER; BRCA1 PROTEIN; CASE-CONTROL STUDIES; DNA MUTATIONAL ANALYSIS; FEMALE; FOUNDER EFFECT; GENOTYPE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; MUTATION; ODDS RATIO; PEDIGREE; POLAND; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 37349004046     PISSN: 09598278     EISSN: None     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e32809b4d20     Document Type: Article

References (29)

1. Cybulski C, Górski B, Dȩbniak T, Gliniewicz B, Mierzejewski M, Masojć B, et al. (2004a). NBS1 is a prostate cancer susceptibility gene. Cancer Res 64:1215-1223.
2. Cybulski C, Gorski B, Huzarski T, Masojc B, Mierzejewski M, Debniak T, et al. (2004b). CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet 75:1131-1135.
3. Dong X, Wang L, Taniguchi K, Wang X, Cunningham JM, McDonnell SK, et al. (2003). Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet 72:270-280.
4. Debniak T, Gorski B, Cybulski C, Jakubowska A, Kurzawski G, Kladny J, et al. (2003). Increased risk of breast cancer in relatives of malignant melanoma patients from families with strong cancer familial aggregation. Eur J Cancer Prev 12:241-245.
5. Edwards SM, Kote-Jarai Z, Meitz J, Hamoudi R, Hope Q, Osin P, et al. (2003). Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 72:1-12.
6. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE (1994). Risks of cancer in BRCA1-mutation carriers. Lancet 343:692-695.
7. Gayther SA, Warren W, Mazoyer S, Russel PA, Harrington PA, Chiano M, et al. (1995). Germline mutations of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet 11:428-433.
8. Gayther SA, de Foy KA, Harrington P, Pharoah P, Dunsmuir WD, Edwards SM, et al. (2000). The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. Cancer Res 60:4513-4518.
9. Giusti RM, Rutter JL, Duray PH, Freedman LS, Konichezky M, Fisher-Fischbein J, et al. (2003). A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology. J Med Genet 40:787-792.
10. Gorski B, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Grzybowska E, et al. (2004). A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer 110:683-686.
11. Gorski B, Cybulski C, Huzarski T, Byrski T, Gronwald J, Jakubowska A, et al. (2005). Breast cancer predisposing alleles in Poland. Breast Cancer Res Treat 92:19-24.
12. Gronwald J, Huzarski T, Byrski B, Medrek K, Menkiszak J, Monteiro AN, et al. (2006). Cancer risks in first degree relatives of BRCA1 mutation carriers: effects of mutation and proband disease status. J Med Genet 43:424-428.
13. Hamel N, Kotar K, Foulkes WD (2003). Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer. BMC Med Genet 4:7.
14. Holt JT, Thompson ME, Szabo C, Robinson-Benion C, Arteaga CL, King MC, Jensen RA (1996). Growth retardation and tumour inhibition by BRCA1. Nat Genet 12:298-302.
15. Hubert A, Peretz T, Manor O, Kaduri L, Wienberg N, Lerer I, et al. (1999). The Jewish Ashkenazi founder mutations in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer. Am J Hum Genet 65:921-924.
16. Ikonen T, Matikainen MP, Syrjakoski K, Mononen N, Koivisto PA, Rokman A, et al. (2003). BRCA1 and BRCA2 mutations have no major role in predisposition to prostate cancer in Finland. J Med Genet 40:e98.
17. Kirchhoff T, Kauff ND, Mitra N, Nafa K, Huang H, Palmer C, et al. (2004). BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res 10:2918-2921.
18. Lehrer S, Fodor F, Stock RG, Stone NN, Eng C, Song HK, McGovern M (1998). Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer. Br J Cancer 78:771-773.
19. Nastiuk KL, Mansukhani M, Terry MB, Kularatne P, Rubin MA, Melamed J, et al. (1999). Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men. Prostate 40:172-177.
20. Neuhausen SL, Mazoyer S, Friedman L, Stratton M, Offit K, Caligo A, et al. (1996). Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. Am J Hum Genet 58: 271-280.
21. Rennert G, Dishon S, Rennert HS, Fares F (2005). Differences in the characteristics of families with BRCA1 and BRCA2 mutations in Israel. Eur J Cancer Prev 14:357-361.
22. Seppala EH, Ikonen T, Mononen N, Autio V, Rokman A, Matikainen MP, et al. (2003). CHEK2 variants associate with hereditary prostate cancer. Br J Cancer 89:1966-1970.
23. Sinclair CS, Berry R, Schaid D, Thibodeau SN, Couch FJ (2000). BRCA1 and BRCA2 have a limited role in familial prostate cancer. Cancer Res 60: 1371-1375.
24. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M (1997). The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336:1401-1408.
25. Thompson D, Easton DF, Breast Cancer Linkage Consortium (2002a). Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94:1358-1365.
26. Thompson D, Easton D, Breast Cancer Linkage Consortium (2002b). Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomarkers Prev 11:329-336.
27. Vazina A, Baniel J, Yaacobi Y, Shtriker A, Engelstein D, Leibovitz I, et al. (2000). The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel. Br J Cancer 83:463-466.
28. Warner E, Foulkes W, Goodwin P, Meschino W, Blondal J, Paterson C, et al. (1999). Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 91:1241-1247.
29. Zuhlke KA, Madeoy JJ, Beebe-Dimmer J, White KA, Griffin A, Lange EM, et al. (2004). Truncating BRCA1 mutations are uncommon in a cohort of hereditary prostate cancer families with evidence of linkage to 17q markers. Clin Cancer Res 10:5975-5980.